ROYALTY PHARMA
Revolution Medicines Secures $2 Billion Funding Deal with Royalty Pharma for RAS Cancer Drug Development
Revolution Medicines partnered with Royalty Pharma on a $2 billion flexible funding agreement to support global development and commercialization of its RAS(ON) inhibitor portfolio for cancer treatment.
Royalty Pharma Secures 99.9% Shareholder Approval for $1.1 Billion External Manager Acquisition
Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.
FDA Approves Ferring Pharmaceuticals' New Manufacturing Facility for Bladder Cancer Gene Therapy ADSTILADRIN
The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer.
Biogen Secures $250M from Royalty Pharma to Advance Lupus Antibody into Phase III Trials
Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development.
Syndax Highlights FDA-Approved Therapies and Anticipated Milestones at J.P. Morgan Healthcare Conference
Syndax launched Revuforj (revumenib) for relapsed/refractory acute leukemia with KMT2A translocation, receiving NCCN guideline inclusion for AML and ALL.
Vertex Records First Casgevy Sale, Intra-Cellular Therapies Reports Positive Caplyta Trial Results
Vertex Pharmaceuticals reported its first commercial sale of Casgevy, a CRISPR gene therapy for sickle cell disease, generating $2 million in revenue from a patient infusion.
BRAIN Biotech AG Secures €128.88 Million Royalty Monetization Deal for Deucrictibant
BRAIN Biotech AG заключила сделку по монетизации роялти на сумму до 128,88 млн евро с Royalty Pharma в отношении исследуемого фармацевтического соединения деукриктибант.